Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07517497

The Course of Acute Respiratory Failure in Geriatric Patients With Hip Fracture Using Different Modes of a Vibroacoustic Device for the Lungs

A medical professional trained in the procedure and use of the device will conduct the vibroacoustic therapy session. He will also take blood samples.

In the control group, patients will undergo vibroacoustic pulmonary therapy in the "Pneumonia" mode, and in the control group, in the "Prevention" mode. Vibroacoustic pulmonary therapy will be conducted over a period of 5 days. A similar algorithm of actions is planned for both groups. VALT sessions will be conducted 4-6 times a day for 5 minutes in combination with treatment according to the protocol for the use of "Vibroacoustic Therapy" of the lungs of the Ministry of Health of the Republic of Kazakhstan. The device's emitters will be applied to the affected areas of the lungs. Since the device has long cords for the emitters and is portable, it is not difficult to change the patient's position and does not require their active participation, which is important for patients on ventilators and with limited mobility.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Vibration Respiratory Complications

Age range

60 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Astana medical university

Astana, 010000, Kazakhstan

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • respiratory failure;
  • hip fracture;
  • Injury Severity Score no higher than 8 points.

Exclusion criteria

  • All contraindications for use of the device:
  • terminal condition of the patient;
  • shock;
  • paradoxical pathological breathing;
  • hypertensive crisis;
  • severe hypocoagulation with a risk of hematoma formation or bleeding in the projection of exposure;
  • severe hypercoagulation, risk of thrombus/embolus migration along the main vessels in the area of exposure;
  • acute cerebrovascular accident in the first 1-3 days;
  • brain edema;
  • presence of multiple purulent or burn wound surfaces in the area of exposure;
  • presence of unstable rib fractures;
  • pneumomediastinum and/or subcutaneous emphysema of the chest;
  • osteomyelitis of the ribs and/or thoracic spine;
  • spinal fracture without orthopedic fixation;
  • chest or abdominal trauma with bleeding;
  • Injury Severity Score greater than 8 points;
  • concomitant diseases in the stage of decompensation.

Treatment and study plan

Vibrolung

Device

BARK VibroLUNG vibroacoustic device (No. RK-MT-7No.013611 dated October 7, 2014). The device is designed for the treatment and prevention of respiratory diseases. The device operates on the principle of exposure to a powerful vibroacoustic signal generated by special emitters. During the procedure, the emitters are pressed against the surface of the chest, and the procedure lasts an average of 5 minutes. The frequency of the signal constantly changes and has complex modulation, which ensures maximum effectiveness. Depending on the selected program, the signal can cause the effect of percussion, soft vibration, smooth alternation of acoustic signal and vibration, or combinations thereof.

Primary outcomes

  1. Arterial blood gases

    Time frame: Day 1

    On day 1 of vibroacoustic therapy, arterial blood sampling will be performed to determine PaO2 (mmHg), PaC02 (mmHg), as well as for dynamics during transfer to the specialized department.

Secondary outcomes

  1. Chest X-ray

    Time frame: Day 1

    Chest X-ray at admission and after vibroacoustic therapy sessions at least twice in total, with technical capabilities(The X-ray image)

Study contacts

Contact information is provided by the study sponsor or research team.

Assema Bekniyazova

CONTACT

[email protected]

87752305441

Sponsors and collaborators

Lead sponsor

Astana Medical University

Other

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 8, 2026
Registry last updated
Apr 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.